| アブストラクト | Background Suzetrigine is a non-opioid analgesic approved for moderate-to-severe acute pain. Whether its early postmarketing adverse-event reporting differs from traditional opioids is uncertain. We tested a prespecified respiratory-depression question and secondary sedation and gastrointestinal (GI) reporting domains. Methods We analyzed US Food and Drug Administration Adverse Event Reporting System/Adverse Event Monitoring System quarterly American Standard Code for Information Interchange extracts from 2025 Q2 through 2026 Q1. After latest-version deduplication, the main cohort comprised adult or age-missing US reports listing suzetrigine or exactly one of oxycodone, hydromorphone, morphine, or tramadol as the primary suspect; misuse/overdose-related reports were excluded, but the cohort was not indication-matched. The primary endpoint was the exact MedDRA preferred term "Respiratory depression," with minimum counts of 10 suzetrigine and 20 comparator reports. Secondary domains were sedation and GI events. Cohort-restricted reporting odds ratios (RORs) were stratified by calendar quarter. The prespecified acute/postoperative restriction was the most clinically aligned comparison; reporter-occupation restrictions were post hoc. No case-level causality assessment was performed. Results The cohort included 894 suzetrigine and 2,365 opioid reports. Respiratory depression appeared in 0/894 and 11/2,365 reports; the primary comparison was non-estimable. Sedation reporting was 33/894 versus 52/2,365 (Mantel-Haenszel ROR 1.77, 95% confidence interval (CI) 1.13-2.76; Holm-adjusted p=0.0244), and GI reporting was 76/894 versus 157/2,365 (ROR 1.31, 95% CI 0.98-1.74; adjusted p=0.0688). The most clinically aligned acute/postoperative restriction attenuated sedation to ROR 1.03 (95% CI 0.56-1.89). In post hoc reporter analyses, consumer-only sedation occurred in 16 of 277 suzetrigine reports and 30 of 1,647 pooled-opioid reports (ROR 3.13, 95% CI 1.66-5.88). Sedation administered exclusively by health care professionals occurred in eight of 295 suzetrigine reports and 17 of 481 pooled-opioid reports, failing to meet the 20-event comparator threshold. Conclusions The respiratory comparison was non-estimable. Sedation reporting was elevated in the main cohort; consumer-only estimates were elevated for sedation and GI events. In the acute/postoperative restriction, both domain confidence intervals included 1. These patterns are compatible with reporting bias or channeling but establish neither their cause nor clinical equivalence. Zero respiratory reports do not establish safety. Denominator-based studies are needed. |